Divi’s Laboratories Limited – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹2,831 Crore
    • QoQ Change: +8.72%
    • YoY Change: +9.52%
  • Previous Quarter (Q3 FY26): ₹2,604 Crore
  • Previous Year (Q4 FY25): ₹2,585 Crore
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹751 Crore
    • QoQ Change: +28.82%
    • YoY Change: +13.44%
  • Previous Quarter (Q3 FY26): ₹583 Crore
  • Previous Year (Q4 FY25): ₹662 Crore
• QoQ Performance:
  • Revenue Trend: Revenue improved steadily quarter-on-quarter with strong operational momentum.
    
  • Profit Trend: Profit growth significantly outpaced revenue growth due to margin improvement and efficient cost control.

Margin Analysis

Drivers:

• Better utilization of manufacturing capacities.
• Inventory movement supported profitability.
• Other expenses remained under control sequentially.
• Strong operating leverage improved margins.
• Finance cost remained negligible.

Insight:

• Divi’s continued to maintain industry-leading operating efficiency with strong earnings conversion and low leverage.

Earning quality check

Key Drivers:

• Operating cash inflow increased to ₹2,738 Cr versus ₹1,653 Cr YoY.
• Cash generated from operations rose strongly to ₹3,600 Cr.
• Low finance cost indicates strong balance sheet quality.
• Strong depreciation growth reflects capacity expansion.
• Working capital remained well managed despite inventory build-up.

Interpretations:

• Earnings quality remains very strong with healthy cash conversion, minimal leverage, and sustained operational efficiency.

balance sheet Analysis

• Total Assets FY26: ₹20,033 Cr
• Total Assets FY25: ₹16,932 Cr
  
• Total Liabilities FY26: ₹3,272 Cr
• Total Liabilities FY25: ₹1,963 Cr
  
• Total Equity FY26: ₹16,761 Cr
• Total Equity FY25: ₹14,969 Cr

Insight:

• Significant increase in capital work-in-progress indicates ongoing expansion projects.
• Equity base strengthened through retained earnings.
• Company continues to maintain a very low leverage profile.

key risks

• Export market dependency.
• Pricing pressure in generic APIs.
• Regulatory risks in pharmaceutical manufacturing.
• Inventory build-up may impact working capital efficiency.
• Currency fluctuation risks due to global exposure.

management strategy signals

Focus Area:

• Expansion of manufacturing capacities.
• Strengthening custom synthesis business.
• Focus on regulated markets.
• Product diversification.
• Long-term investment in high-value APIs.

Financial metrics table

Quarterly Performance Context